12 October
Access to rheumatoid arthritis (RA) drugs still varies widely across Europe, according to a new report. And large variations of affordability across the region can lead to different assessments of the cost-effectiveness of the treatments by regulators, thus exacerbating the inequality. The European Journal of Health Economics (EJHE) report also highlights that speed and levels of access depend on where patients live: RA patients treated with biologics range from 30% in Norway to less than 1% in Bulgaria.
The report's authors call on the European authorities to realize the potential benefits of early and wide access to innovative RA treatments. Two million people are affected by the disease in Europe, and disease remission can be a realistic goal with the right treatments at the right time.
Brian Ager, director general of EFPIA, commented: "It is particularly appropriate that this report is published today, on World Arthritis Day..We hope it will stimulate discussions on how we achieve the optimal use of new technologies and treatment for all patients."
The report - the latest in a series of EJHE publications examining 'the burden of rheumatoid arthritis and access to treatment: uptake of new therapies' - is available for download here: http://www.comparatorreports.se
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.